{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:38:12Z","timestamp":1783708692884,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40264-021-01089-5","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T10:03:04Z","timestamp":1627898584000},"page":"929-938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["NSAIDs and COVID-19: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-2817","authenticated-orcid":false,"given":"Nicholas","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9763-5974","authenticated-orcid":false,"given":"Pauline","family":"Bosco-Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-0819","authenticated-orcid":false,"given":"Nicolas","family":"Thurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4005-7928","authenticated-orcid":false,"given":"Patrick","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-1167","authenticated-orcid":false,"given":"C\u00e9cile","family":"Droz-Perroteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"issue":"4","key":"1089_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.therap.2020.05.003","volume":"75","author":"J Micallef","year":"2020","unstructured":"Micallef J, Soeiro T, Jonville-Bera AP, French Society of Pharmacology T. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. Therapie. 2020;75(4):355\u201362.","journal-title":"Therapie"},{"issue":"4","key":"1089_CR2","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1089_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.","journal-title":"Cell"},{"issue":"7","key":"1089_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40264-020-00953-0","volume":"43","author":"N Moore","year":"2020","unstructured":"Moore N, Carleton B, Blin P, Bosco-Levy P, Droz C. Does ibuprofen worsen COVID-19? Drug Saf. 2020;43(7):611\u20134.","journal-title":"Drug Saf"},{"issue":"7","key":"1089_CR5","doi-asserted-by":"publisher","first-page":"e00014","DOI":"10.1128\/JVI.00014-21","volume":"95","author":"JS Chen","year":"2021","unstructured":"Chen JS, Alfajaro MM, Chow RD, Wei J, Filler RB, Eisenbarth SC, et al. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. J Virol. 2021;95(7):e00014-21.","journal-title":"J Virol"},{"issue":"3","key":"1089_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/bcp.14514","volume":"87","author":"R Vaja","year":"2021","unstructured":"Vaja R, Chan JSK, Ferreira P, Harky A, Rogers LJ, Gashaw HH, et al. The COVID-19 ibuprofen controversy: a systematic review of NSAIDs in adult acute lower respiratory tract infections. Br J Clin Pharmacol. 2021;87(3):776\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1089_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40122-020-00173-5","volume":"9","author":"JV Pergolizzi Jr","year":"2020","unstructured":"Pergolizzi JV Jr, Varrassi G, Magnusson P, LeQuang JA, Paladini A, Taylor R, et al. COVID-19 and NSAIDS: a narrative review of knowns and unknowns. Pain Ther. 2020;9(2):353\u20138.","journal-title":"Pain Ther"},{"key":"1089_CR8","doi-asserted-by":"publisher","unstructured":"Reese JT, Coleman B, Chan L, Blau H, Callahan TJ, Cappelletti L, et al. Cyclooxygenase inhibitor use is associated with increased COVID-19 severity. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.04.13.21255438.","DOI":"10.1101\/2021.04.13.21255438"},{"issue":"4","key":"1089_CR9","doi-asserted-by":"publisher","DOI":"10.5812\/archcid.106847","volume":"15","author":"HR Samimagham","year":"2020","unstructured":"Samimagham HR, Arabi M, Hooshyar D, KazemiJahromi M. The association of non-steroidal anti-inflammatory drugs with COVID-19 severity and mortality. Arch Clin Infect Dis. 2020;15(4):e106847.","journal-title":"Arch Clin Infect Dis."},{"issue":"1","key":"1089_CR10","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1038\/s41598-021-84539-5","volume":"11","author":"J Park","year":"2021","unstructured":"Park J, Lee SH, You SC, Kim J, Yang K. Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19. Sci Rep. 2021;11(1):5087.","journal-title":"Sci Rep"},{"key":"1089_CR11","doi-asserted-by":"publisher","unstructured":"Chang TS, Ding Y, Freund MK, Johnson R, Schwarz T, Yabu JM, et al. Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.07.03.20145581.","DOI":"10.1101\/2020.07.03.20145581"},{"issue":"5","key":"1089_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/art.41593","volume":"73","author":"JS Chandan","year":"2021","unstructured":"Chandan JS, Zemedikun DT, Thayakaran R, Byne N, Dhalla S, Acosta-Mena D, et al. Non-steroidal anti-inflammatory drugs and susceptibility to COVID-19. Arthritis Rheumatol. 2021;73(5):731\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1089_CR13","doi-asserted-by":"publisher","first-page":"105095","DOI":"10.1016\/j.jbspin.2020.105095","volume":"88","author":"F Costantino","year":"2021","unstructured":"Costantino F, Bahier L, Tarancon LC, Leboime A, Vidal F, Bessalah L, et al. COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Jt Bone Spine. 2021;88(1):105095.","journal-title":"Jt Bone Spine."},{"issue":"1","key":"1089_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40121-020-00363-w","volume":"10","author":"LC Abu Esba","year":"2021","unstructured":"Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study. Infect Dis Ther. 2021;10(1):253\u201368.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"1089_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859\u201366.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1089_CR16","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1007\/s11606-020-05937-5","volume":"35","author":"Z Imam","year":"2020","unstructured":"Imam Z, Odish F, Armstrong J, Elassar H, Dokter J, Langnas E, et al. Independent correlates of hospitalization in 2040 patients with COVID-19 at a large hospital system in Michigan, United States. J Gen Intern Med. 2020;35(8):2516\u20137.","journal-title":"J Gen Intern Med"},{"issue":"9","key":"1089_CR17","doi-asserted-by":"publisher","first-page":"e1003308","DOI":"10.1371\/journal.pmed.1003308","volume":"17","author":"LC Lund","year":"2020","unstructured":"Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study. PLoS Med. 2020;17(9):e1003308.","journal-title":"PLoS Med"},{"issue":"1","key":"1089_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1620\/tjem.252.73","volume":"252","author":"NM Alamdari","year":"2020","unstructured":"Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A, et al. Mortality risk factors among hospitalized COVID-19 patients in a Major Referral Center in Iran. Tohoku J Exp Med. 2020;252(1):73\u201384.","journal-title":"Tohoku J Exp Med"},{"issue":"8","key":"1089_CR19","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.3390\/jcm9082586","volume":"9","author":"E Bruce","year":"2020","unstructured":"Bruce E, Barlow-Pay F, Short R, Vilches-Moraga A, Price A, McGovern A, et al. Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J Clin Med. 2020;9(8):2586.","journal-title":"J Clin Med"},{"issue":"11","key":"1089_CR20","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1001\/jamainternmed.2020.3596","volume":"180","author":"S Gupta","year":"2020","unstructured":"Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically ill patients with Coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436\u201347.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"1089_CR21","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s10072-020-04541-z","volume":"41","author":"JM Hwang","year":"2020","unstructured":"Hwang JM, Kim JH, Park JS, Chang MC, Park D. Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study. Neurol Sci. 2020;41(9):2317\u201324.","journal-title":"Neurol Sci"},{"issue":"4","key":"1089_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/joim.13119","volume":"288","author":"Z Imam","year":"2020","unstructured":"Imam Z, Odish F, Gill I, O\u2019Connor D, Armstrong J, Vanood A, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020;288(4):469\u201376.","journal-title":"J Intern Med"},{"key":"1089_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219517","author":"AY Wong","year":"2021","unstructured":"Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219517.","journal-title":"Ann Rheum Dis"},{"key":"1089_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00104-1","author":"TM Drake","year":"2021","unstructured":"Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC clinical characterisation protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatol. 2021. https:\/\/doi.org\/10.1016\/S2665-9913(21)00104-1.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1089_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","volume":"181","author":"S Gupta","year":"2021","unstructured":"Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41\u201351.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"1089_CR26","doi-asserted-by":"publisher","first-page":"1259.e5","DOI":"10.1016\/j.cmi.2020.06.003","volume":"26","author":"E Rinott","year":"2020","unstructured":"Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020;26(9):1259.e5-1259.e7.","journal-title":"Clin Microbiol Infect"},{"key":"1089_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1056","author":"HE Jeong","year":"2020","unstructured":"Jeong HE, Lee H, Shin HJ, Choe YJ, Filion KB, Shin JY. Association between NSAIDs use and adverse clinical outcomes among adults hospitalized with COVID-19 in South Korea: a nationwide study. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa1056.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1089_CR28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/cts.12904","volume":"13","author":"K Kragholm","year":"2020","unstructured":"Kragholm K, Gerds TA, Fosbol E, Porsborg Andersen M, Phelps M, Butt JH, et al. Association between prescribed ibuprofen and severe COVID-19 infection: a nationwide register-based cohort study. Clin Transl Sci. 2020;13(6):1103\u20137.","journal-title":"Clin Transl Sci"},{"issue":"Suppl 4","key":"1089_CR29","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.annemergmed.2020.09.051","volume":"76","author":"SJ Perkins","year":"2020","unstructured":"Perkins SJ, Holmes AR, Nelson JR, Hirschl JR, Chopra Z, Medlin R, et al. Clinical outcomes among COVID-19 patients taking non-steroidal anti-inflammatory drugs. Ann Emerg Med. 2020;76(Suppl 4):S17.","journal-title":"Ann Emerg Med"},{"key":"1089_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X211012754","author":"A Sahai","year":"2021","unstructured":"Sahai A, Bhandari R, Godwin M, McIntyre T, Chung MK, Iskandar JP, et al. Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. Vasc Med. 2021. https:\/\/doi.org\/10.1177\/1358863X211012754.","journal-title":"Vasc Med"},{"issue":"2","key":"1089_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000375362","volume":"131","author":"W Qiao","year":"2015","unstructured":"Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015;131(2):97\u2013106.","journal-title":"Cardiology"},{"issue":"5","key":"1089_CR32","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.therap.2020.07.008","volume":"75","author":"J Micallef","year":"2020","unstructured":"Micallef J, Soeiro T, Jonville-Bera AP. COVID-19 and NSAIDs: primum non nocere. Therapie. 2020;75(5):514\u20135.","journal-title":"Therapie"},{"issue":"19","key":"1089_CR33","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","volume":"41","author":"GM Kuster","year":"2020","unstructured":"Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801\u20133.","journal-title":"Eur Heart J"},{"issue":"6","key":"1089_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40264-020-00935-2","volume":"43","author":"G Trifiro","year":"2020","unstructured":"Trifiro G, Crisafulli S, Ando G, Racagni G, Drago F, Italian Society of P. Should patients receiving ace inhibitors or angiotensin receptor blockers be switched to other antihypertensive drugs to prevent or improve prognosis of novel Coronavirus disease 2019 (COVID-19)? Drug Saf. 2020;43(6):507\u20139.","journal-title":"Drug Saf"},{"issue":"25","key":"1089_CR35","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin\u2013aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382(25):2431\u201340.","journal-title":"N Engl J Med"},{"issue":"25","key":"1089_CR36","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of COVID-19. N Engl J Med. 2020;382(25):2441\u20138.","journal-title":"N Engl J Med"},{"key":"1089_CR37","doi-asserted-by":"publisher","unstructured":"Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, et al. Hypertension and renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.24.20077388.","DOI":"10.1101\/2020.04.24.20077388"},{"issue":"9","key":"1089_CR38","doi-asserted-by":"publisher","first-page":"e040644","DOI":"10.1136\/bmjopen-2020-040644","volume":"10","author":"H Dambha-Miller","year":"2020","unstructured":"Dambha-Miller H, Albasri A, Hodgson S, Wilcox CR, Khan S, Islam N, et al. Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review. BMJ Open. 2020;10(9):e040644.","journal-title":"BMJ Open"},{"key":"1089_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.186","author":"K Sriram","year":"2020","unstructured":"Sriram K, Insel PA. Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence. Clin Pharmacol Ther. 2020. https:\/\/doi.org\/10.1002\/cpt.186.","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"1089_CR40","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with COVID-19. N Engl J Med. 2020;382(17):1653\u20139.","journal-title":"N Engl J Med"},{"key":"1089_CR41","doi-asserted-by":"publisher","unstructured":"Chen JS, Alfajaro MM, Wei J, Chow RD, Filler RB, Eisenbarth SC, et al. Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.09.24.312769.","DOI":"10.1101\/2020.09.24.312769"},{"issue":"6","key":"1089_CR42","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s10787-020-00755-x","volume":"28","author":"MT Kelleni","year":"2020","unstructured":"Kelleni MT. ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror. Inflammopharmacology. 2020;28(6):1477\u201380.","journal-title":"Inflammopharmacology"},{"key":"1089_CR43","doi-asserted-by":"publisher","first-page":"110982","DOI":"10.1016\/j.biopha.2020.110982","volume":"133","author":"MT Kelleni","year":"2021","unstructured":"Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021;133:110982.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"1089_CR44","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.bdj.2014.330","volume":"216","author":"E Bailey","year":"2014","unstructured":"Bailey E, Worthington H, Coulthard P. Ibuprofen and\/or paracetamol (acetaminophen) for pain relief after surgical removal of lower wisdom teeth, a Cochrane systematic review. Br Dent J. 2014;216(8):451\u20135.","journal-title":"Br Dent J"},{"issue":"9","key":"1089_CR45","first-page":"CD008659","volume":"2015","author":"RA Moore","year":"2015","unstructured":"Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults\u2014an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;;2015(9):CD008659.","journal-title":"Cochrane Database Syst Rev."},{"issue":"11","key":"1089_CR46","first-page":"CD010794","volume":"2015","author":"RA Moore","year":"2015","unstructured":"Moore RA, Wiffen PJ, Derry S, Maguire T, Roy YM, Tyrrell L. Non-prescription (OTC) oral analgesics for acute pain\u2014an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;2015(11):CD010794.","journal-title":"Cochrane Database Syst Rev."},{"issue":"10256","key":"1089_CR47","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","volume":"396","author":"RHM Furtado","year":"2020","unstructured":"Furtado RHM, Berwanger O, Fonseca HA, Correa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959\u201367.","journal-title":"Lancet"},{"issue":"10274","key":"1089_CR48","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605\u201312.","journal-title":"Lancet"},{"issue":"5","key":"1089_CR49","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1542\/peds.107.5.1108","volume":"107","author":"SM Lesko","year":"2001","unstructured":"Lesko SM, O\u2019Brien KL, Schwartz B, Vezina R, Mitchell AA. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics. 2001;107(5):1108\u201315.","journal-title":"Pediatrics"},{"issue":"10","key":"1089_CR50","doi-asserted-by":"publisher","first-page":"13185","DOI":"10.1096\/fj.202001807","volume":"34","author":"S De Flora","year":"2020","unstructured":"De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J. 2020;34(10):13185\u201393.","journal-title":"FASEB J"},{"key":"1089_CR51","doi-asserted-by":"publisher","first-page":"579944","DOI":"10.3389\/fphar.2020.579944","volume":"11","author":"P Sestili","year":"2020","unstructured":"Sestili P, Fimognari C. Paracetamol-induced glutathione consumption: is there a link with severe COVID-19 illness? Front Pharmacol. 2020;11:579944.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1089_CR52","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/antiox9070624","volume":"9","author":"F Silvagno","year":"2020","unstructured":"Silvagno F, Vernone A, Pescarmona GP. The role of glutathione in protecting against the severe inflammatory response triggered by COVID-19. Antioxidants (Basel). 2020;9(7):624.","journal-title":"Antioxidants (Basel)"},{"key":"1089_CR53","doi-asserted-by":"publisher","first-page":"625295","DOI":"10.3389\/fphar.2020.625295","volume":"11","author":"S Verd","year":"2020","unstructured":"Verd S, Verd M. Commentary: paracetamol-induced glutathione consumption: is there a link with severe COVID-19 illness? Front Pharmacol. 2020;11:625295.","journal-title":"Front Pharmacol"},{"key":"1089_CR54","doi-asserted-by":"publisher","first-page":"m1555","DOI":"10.1136\/bmj.m1555","volume":"369","author":"I Torjesen","year":"2020","unstructured":"Torjesen I. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ. 2020;369:m1555.","journal-title":"BMJ"},{"key":"1089_CR55","unstructured":"WHO. Updated: WHO Now Doesn't Recommend Avoiding Ibuprofen For COVID-19 Symptoms 2020. https:\/\/www.sciencealert.com\/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms. Accessed 1 Mar 2021."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01089-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01089-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01089-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T16:06:47Z","timestamp":1629216407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01089-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01089-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"5 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to assist in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nicholas Moore has provided expert advice to pharmaceutical companies and regulators regarding the risks associated with low-dose NSAIDs and other analgesics, over the last 30 + years. Bordeaux PharmacoEpi conducts postmarketing safety or efficacy studies funded by industry at the request of regulatory authorities, in addition to publicly funded studies, none of which relate to the topic reported in this article. These studies are listed in the European PAS register (). Pauline Bosco-Levy, Nicolas Thurin, Patrick Blin, and C\u00e9cile Droz-Perroteau are employees of Bordeaux PharmacoEpi and their salaries are generated by post-authorisation studies requested, or not, by regulatory authorities. They have no competing interests within the topic of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable for observational studies or meta-analyses.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. All data used for the meta-analysis are provided in the tables and figures, based on publicly available data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data transparency"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Initial idea and overall supervision: NM. Related search: NM, NT, CDP, PB. Data collection: NM, PBL, NT. Validation and statistics: NM, NT, PBL, PB, CD. There were no disagreements between authors and all authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}